Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Blackstone to Sell Alinamin to MBK Partners
July 4, 2024
- Chugai Grabs Japan’s Best-Paying Pharma Crown Yet Again: Jiho Tally
July 3, 2024
- Mochida Files EPA Agent Epadel in China
July 3, 2024
- China Approves Xtandi for Metastatic Hormone-Sensitive Prostate Cancer: Astellas
July 3, 2024
- Janssen Rebranded as J&J in Japan as Part of Global Move
July 2, 2024
- Medipal/JCR’s MPS IIIB Drug Now in Line to Enter Clinic
July 2, 2024
- MSD to Transfer Belsomra Distribution Rights to Daiichi Sankyo in Japan
July 2, 2024
- MSD Files Keytruda for Malignant Pleural Mesothelioma in Japan
July 2, 2024
- Eisai to Go Solo on Its 1st ADC after BMS Exits Deal
July 2, 2024
- Moderna Files Spikevax as Booster for Kids Aged 6 Months to 4 Years
July 1, 2024
- Daiichi Sankyo’s ADC Arbitration Win Finalized with No Appeal
July 1, 2024
- Healios Pushes Back Definitive MultiStem Deal with Nobelpharma
July 1, 2024
- Xocova Slashes Risk of Hospitalization in Real-World Setting
July 1, 2024
- EA Pharma Grants Global Rights to IBD Drugs to Ensho
July 1, 2024
- Pfizer, Viatris to Copromote Cibinqo, Litfulo in Japan
July 1, 2024
- Kyowa Kirin Files Pen Version of Lumicef in Japan
July 1, 2024
- Eisai’s Alzheimer’s Med Leqembi Now Available in China
July 1, 2024
- Pfizer Seeks Japan Approval for Ulcerative Colitis Drug
July 1, 2024
- Pfizer Files Hemophilia B Gene Therapy in Japan
July 1, 2024
- Physician Predicts 30-40% Switch Rate for Chugai’s PNH Drug Piasky
June 28, 2024
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…